Once-weekly Bortezomib As the Standard of Care in Multiple Myeloma: Results from an International Survey of Physicians

Overview

Journal Blood Cancer J

Date 2023 Nov 5

PMID 37926718

Authors

Rahul Banerjee

Bo Wang

Larry D Anderson Jr

Georgia McCaughan

Nikita Mehra

Andrew J Cowan

S Vincent Rajkumar

Gurbakhash Kaur

Affiliations

Soon will be listed here.

Citing Articles

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.

Rajkumar S Am J Hematol. 2024; 99(9):1802-1824.

PMID: 38943315 PMC: 11404783. DOI: 10.1002/ajh.27422.

Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma.

Banerjee R, Cowan A, Ortega M, Missimer C, Carpenter P, Ueda Oshima M Clin Lymphoma Myeloma Leuk. 2024; 24(7):446-454.e3.

PMID: 38521640 PMC: 11189752. DOI: 10.1016/j.clml.2024.02.013.

Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.

Hoff F, Banerjee R, Khan A, McCaughan G, Wang B, Wang X Blood Cancer J. 2024; 14(1):52.

PMID: 38519476 PMC: 10959949. DOI: 10.1038/s41408-024-01034-6.

References

Merz M, Salwender H, Haenel M, Mai E, Bertsch U, Kunz C . Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015; 100(7):964-9. PMC: 4486231. DOI: 10.3324/haematol.2015.124347. View

Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A . Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3,.... Lancet Oncol. 2020; 21(10):1317-1330. PMC: 7591827. DOI: 10.1016/S1470-2045(20)30452-6. View

Leung N, Rajkumar S . Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023; 13(1):46. PMC: 10060259. DOI: 10.1038/s41408-023-00806-w. View

Durie B, Hoering A, Sexton R, Abidi M, Epstein J, Rajkumar S . Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous.... Blood Cancer J. 2020; 10(5):53. PMC: 7214419. DOI: 10.1038/s41408-020-0311-8. View

Voorhees P, Kaufman J, Laubach J, Sborov D, Reeves B, Rodriguez C . Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945. PMC: 7441167. DOI: 10.1182/blood.2020005288. View

Moffett P, Moore G . The standard of care: legal history and definitions: the bad and good news. West J Emerg Med. 2011; 12(1):109-12. PMC: 3088386. View

Richardson P, Jacobus S, Weller E, Hassoun H, Lonial S, Raje N . Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022; 387(2):132-147. PMC: 10040899. DOI: 10.1056/NEJMoa2204925. View

Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M . Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020; 396(10262):1563-1573. DOI: 10.1016/S0140-6736(20)32292-3. View

Mateos M, Dimopoulos M, Cavo M, Suzuki K, Jakubowiak A, Knop S . Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2017; 378(6):518-528. DOI: 10.1056/NEJMoa1714678. View

10.

McCaughan G, Gandolfi S, Moore J, Richardson P . Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. Br J Haematol. 2022; 199(2):190-204. PMC: 9796722. DOI: 10.1111/bjh.18295. View

11.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M . Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017; 376(14):1311-1320. PMC: 6201242. DOI: 10.1056/NEJMoa1611750. View

12.

Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W . Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. Am J Hematol. 2020; 96(3):330-337. DOI: 10.1002/ajh.26074. View

13.

Sidana S, Narkhede M, Elson P, Hastings D, Faiman B, Valent J . Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS One. 2017; 12(3):e0172996. PMC: 5344345. DOI: 10.1371/journal.pone.0172996. View

14.

Taylor C . The use of clinical practice guidelines in determining standard of care. J Leg Med. 2014; 35(2):273-90. DOI: 10.1080/01947648.2014.913460. View

15.

Mateos M, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos M, Heeg B . The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leuk Lymphoma. 2019; 61(3):680-690. DOI: 10.1080/10428194.2019.1675881. View